Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.


NDAQ:AXSM - Post by User

Axsome Therapeutics Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(301)
•••
  • whytestocksX
Post by whytestockson Jun 11, 2024 7:00pm
90 Views
Post# 36083723

Buy Recommendation Issued On AXSM By Guggenheim

Buy Recommendation Issued On AXSM By Guggenheim
News; $AXSM Buy Recommendation Issued On AXSM By Guggenheim2024-06-11 16:30:03 ET Guggenheim analyst issues BUY recommendation for AXSM on June 11, 2024 03:28PM ET. The previous analyst recommendation was Buy. AXSM was trading at $71.07 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...AXSM - Buy Recommendation Issued On AXSM By Guggenheim

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities